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Brucellosis in children 411. Purpose of the guidelines
1. To increase the awareness of pediatricians and other
child care providers, such as family medicine and gen-
eral practitioners, about brucellosis, its varied clinical
presentations and its impact on child health.
2. To provide insight to the epidemiology of brucellosis in
Saudi Arabia, the modes of transmission and preventive
measures.
3. To set a standard scheme for the diagnosis, antimicrobial
therapy, management and follow up of childhood
brucellosis.2. Epidemiology
Brucellosis is endemic in Saudi Arabia with a reported
incidence of 18/100,000 population/year, as reported by
the MOH in 2011. An overall seroprevalence rate of 15% was
found in the Saudi population, and the seroprevalence in
children aged 0e14 years was 10% [1].
The reason for the high prevalence of brucellosis in
Saudi Arabia is attributed, but not limited, to the following:
1. The nomadic life style including animal raising, espe-
cially of sheep and camels.
2. The traditional belief of the great benefit of ingesting
raw milk, especially camel milk.
3. The high rate of animals imported from Africa where the
disease is endemic, with a lag in compliance with na-
tional and international policies of animals screening
and quarantine rules. In Saudi Arabia, the prevalence of
brucella among different animals is high; 8% in camels,
18.7% in cattle, 6.5% in sheep and 9.7% in goats [2].
4. The mixing of different animal herds together, such as
raising sheep and cattle together.
5. The low levels of public awareness about the seriousness
of brucellosis as a human disease.
6. The resistance to slaughtering infected animals.3. Transmission
Brucella spp. are small, gram negative, non-motile, non-
spore-forming, rod shaped (coccobacilli) bacterial organisms.
It is a zoonotic disease caused by the ingestion of raw unpas-
teurizedmilk from infectedanimalsor close contactwith their
secretions. There are different animal reservoirs for different
Brucella spp. that are known to cause human disease:Species Animal Host Virulence
Brucella
melitensis
Goats, sheep, camels þþþþ
Brucella
abortus
Cows, other bovidae animals
and camels
þþþ
Brucella canis Dogs þ
Brucella suis Pigs þOther species include Brucella ovis, Brucella neotomae,
Brucella microti and marine Brucella species (Brucella
pinnipediae and Brucella cetaceae); however, only the
marine species have been reported to rarely cause human
disease [3].
In Saudi Arabia and most of the neighboring countries,
the most prevalent species is Brucella melitensis causing
70e90% of brucellosis cases. Brucella abortus is the second
most common disease causing pathogen. The other species
rarely cause brucellosis.
Transmission of the organism to humans occurs as a
result of:
1. The consumption of unpasteurized raw milk or other
dairy products, especially soft cheese, butter and
cream. Hard cheese, sour milk and yogurt are unlikely to
transmit the disease because of the propionic and lactic
fermentation.
2. Direct contact with the secretions of infected animals or
their products, such as the placenta or aborted
materials.
3. The air borne transmission of aerosolized materials
through open wounds or mucus membranes either in the
animal areas or in the laboratory when dealing with
blood and other infected fluid cultures. It has been
found that direct contact with soil, animal feces and
dust contaminated with Brucella is associated with a
higher risk of infection [4].
4. Vertical transmission, sexual transmission and breast
milk transmission are anecdotally reported routes of
infection.4. Clinical presentation
Most infected children have acute and sub-acute presen-
tation of 2e4 weeks of symptomatology [5,6]. Brucellosis
symptomatology is very variable, in part because of the
variable pathogenicity of different strains. It is known that
B. abortus causes milder disease with either mild symp-
tomatology or focal lesions. However, infection with
B. melitensis is usually associated with a high rate of
bacteremia, short incubation periods, and noticeable
symptoms [3,6,7]. Almost any organ can be affected and
varied complications are reported. Almost 76% of affected
patients present within two weeks of the onset of their
symptoms [4]. Fever and arthritis are the most common
presenting signs. Monoarthritis was more common than
polyarthritis. This may create confusion with pyogenic
arthritis in children; therefore, in a community where
brucella is common, awareness about this entity should
prompt the investigation of this disease, and physicians
should have a high index of suspicion for Brucella arthritis.
The most commonly affected joints were the hip and knee.
Unlike in adults, the sacroiliac joint and the axial skeleton
were rarely affected [4]. Brucella osteomyelitis is rare in
children. Studies showed that only le2% of children with
brucellosis has osteomyelitis [5,6,8]. Neurobrucellosis is
rare in children and it has been reported in only 0.5e1% of
children with brucellosis. The clinical presentation of
neurobrucellosis is variable with meningitis and
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sentations of neurobrucellosis include polyradiculopathy,
myelitis and psychiatric disorders, mainly depression. Rare
CNS manifestations include brain abscess, hydrocephalus,
pesudotumor cerebri, Guillain Barre syndrome, cranial
nerve palsy, cerebral venous sinus thrombosis, subdural and
epidural collection and stroke [9,10,11]. Clinical manifes-
tations of neurobrucellosis range from subtle manifesta-
tion, such as fever and malaise, to frank meningitis. Other
manifestations include cranial nerve neuropathy, hearing
loss, visual disturbances, chronic vomiting, altered senso-
rium and coma and various neurological focal motor defi-
cits. Recovery is typical and sequelae are rare.
Classic general symptoms include the following:
 Headache
 Myalgia/bone pain
 Anorexia/weight loss
 Sweats
 Malodorous perspiration
 Depression, or mood disorders
 Fever
 Arthralgia/arthritis
The main signs are:
 Fever
 Arthritis
 Hepatomegaly
 Splenomegaly
 Neck stiffness
 Miscellaneous (skin rash, cervical nodes, drowsiness,
periorbital swelling, ataxia)
Other rare manifestations include:
- CNS meningitis, encephalitis, meningoencephalitis,
brain abscess, and Guillain Barr syndrome
- Lung pneumonia
- Cardiac endocarditis and myocarditis
- Liver transaminasemia and abscess
- Spleen abscess
- Genitourinary epedidemo-orchitis and nephritis
- Eye uveitis
- Thyroid abscess
- Spine epidural abscess
- Hematologic immune thrombocytopenic purpura and
hemophagocytic syndrome4.1. Diagnosis
Laboratory diagnosis of brucellosis relies on:
1. Positive blood or other sterile body fluid culture, such as
synovial fluid, CSF, and plural fluid, for brucella species.
2. Or, a positive brucella serology test of 1:160, using the
Standard Agglutination Test (SAT) for patients presenting
with symptoms suggestive of brucellosis. For the purpose
of screening and in the absence of clinical indicators of
active brucellosis, a titer of 1:320 or higher is more
specific for the presence of the disease.4.2. Culture
Although positive culture should be the gold standard for
diagnosis, its yield remains suboptimal. The culture yield is
greater in the first two weeks of illness and as the duration
of illness increases the yield decreases. In a patient with
fever and chills and short duration of illness, the culture
yield is up to 90%; however, as the disease duration in-
creases the yield drops to 30%. Most studies have shown a
40e70% yield. Rapid diagnosis of brucella using the new
third generation continuous monitoring blood culture sys-
tems, such as non-radiometric BACTEC or BACT/ALERT, has
shown a better and faster recovery with all positive cul-
tures occurring by day 5e7 of incubation; therefore,
extending the blood culture incubation to 4 weeks for
improving the yield of culture is rarely required [12,13].
4.3. Specimen collection and requisition
Blood is collected aseptically by venipuncture. The volume
withdrawn at a single venipuncture (3e5 ml and 10 ml from
older children) and inoculated into a pediatric vial. For the
diagnosis of bloodstream infection, two “sets” drawn
20 min apart are normally recommended. In infants and
children, partly because the intensity of bacteremia is
greater and partly due to physiological reasons, 3.0 ml in
the specially formatted pediatric vial is acceptable. Inoc-
ulated vials should be transported promptly to the labora-
tory and held at room temperature until they are entered
into the BacTeAlert system. Vials must be incubated up to 5
days routinely, in cases with a high index of suspicion along
with a negative initial blood culture, the incubation period
can be increased up to 21 days.
4.4. Species identification
 Gram stain: Brucella are Gram-negative coccobacilli that
strongly retain the crystal violet and resist counter-
staining. It may be necessary to counterstain for 1e3min.
 For any blood culture that flags positive and is indicative of
Brucella species, 0.5 ml of the blood culture fluid is to be
aspirated from the bottle and inoculated onto a urea slant.
This tube is sealed with parafilm and incubated in CO2 for
24 h. These slants must be checked for a positive reaction
every 2 h and the length of time taken to becomepositive is
documented on the electronic worksheet. Brucella is usu-
ally oxidase positive, catalase positive and urease positive.4.5. Brucella susceptibility testing
Brucella susceptibility testing is performed by E-test for the
following antibiotics: tigecycline, SXT, rifampin, tetracy-
cline, streptomycin and ciprofloxacin. The interpretation is
according to the CLSI guidelines as well as published ref-
erences. Some discrepancy exists between in vitro suscep-
tibility results and in vivo outcomes. This precludes the
exact extrapolation of in vitro results to in vivo application.
However, every attempt should be made to follow suscep-
tibility data in the choice of antimicrobial regimen for the
treatment of brucellosis [13,14,15].
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Because of the lower yield of culture, serological tests
remain the best diagnostic modality available. There are
multiple serological tests for brucella including the stan-
dard agglutination test (SAT), the enzyme linked immuno-
sorbent assay (ELISA), indirect Coombs, brucellacapt,
indirect fluorescent antibody and immunochromatogrphic
lateral flow [13,14]. The most commonly used tests are SAT
and ELISA.
5.1. Standard agglutination test (SAT)
SAT is the most commonly used and most standardized test.
It is based on measuring an agglutination titer of different
serum dilutions against a standardized concentration of
whole brucella cell suspension. It is usually measured by
doubling the serum dilution from 1:20 up to 1:20,480. A
positive titer is 1:160 or more. In endemic areas, there may
be a persistent and continuing exposure to the source of
infection, and therefore there may be a persistent low titer
in the range of 1:80e1:160 in the absence of true infection.
It was found that 2.9 and 2.5% of the healthy Saudi popu-
lation have a titer of 1:160 and 1:320, respectively [1]. Our
study showed that 92% of children with acute brucellosis
have a titer of 1:320 or more [6]. Brucella antibodies can
persist for a long period after acute infection with a median
time to serological cure of 18 months. Among cured
patients, 29% continued to have a titer of 1:320 or higher
2 years or more after infection [16,17]. Therefore, the
interpretation of serology in endemic areas should be
correlated to the clinical presentation. As such, for
screening purposes and in the absence of suggestive
symptomatology, a titer of 1:320 or more should be
taken as the cutoff level for positivity. Coupling SAT with
the 2-mercaptoethanol agglutination test is useful in
differentiating acute from chronic brucellosis. The 2-
mercaptoethanol agglutination test elutes IgM out leaving
IgG. Elevated IgG titers indicate an acute disease. A nega-
tive 2-mercaptoethanol test after therapy indicates a good
response to treatment.
There are a few limitations to the SAT including:
 The inability to diagnose B. canis
 The appearance of cross-reactions of IgM with Franci-
sella tularensis, Escherichia coli O116 and O157, Sal-
monella urbana, Yersinia enterocolitica O: 9, Vibrio
cholerae, Xanthomonas maltophilia, and Afipia
clevelandensis
 The SAT may be negative in presence of disease in rare
occasions
Lack of seroconversion can be attributed to:
 The performance of the SAT early in the course of
infection
 The presence of blocking antibodies
 The prozone phenomenon (i.e. the inhibition of agglu-
tination at low dilutions due to an excess of antibodies or
to nonspecific serum factors)5.2. Enzyme linked immunosorbent assay (ELISA)
The ELISA is performed using 96-well microtiter plates that
are precoated with a standardized antigen, usually purified
lipopolysaccharide. It has the advantage of measuring
different classes of reactive antibodies including IgG, IgA
and IgM. Thus, it has greater ability to differentiate be-
tween acute infection and relapsing infection. Various
studies showed different results regarding the sensitivity of
the ELISA. In general, the sensitivity ranges from 60 to 98%.
In acute brucellosis, the sensitivity and specificity of ELISA
for IgG were found to be 45 and 97%, respectively, and were
79 and 100% for IgM, respectively [18]. Another study found
that the sensitivity and specificity of ELISA for IgG were
84 and 100%, respectively, and 60 and 100% for IgM,
respectively [19]. The sensitivity and specificity of com-
bined of ELISA for IgG and ELISA for IgM are comparable to
that of the SAT [14]. Therefore, the SAT remained the
preferred test of choice for acute brucellosis. However, for
follow up and for the diagnosis of a brucella relapse ELISA is
better as it gives a separate titer for IgG, IgM and IgA and
thus can be used to assess response to therapy and relapse.
The ELISA is the best for detecting brucella antibody in the
cerebrospinal fluid in cases of neurobrucellosis [14].
5.3. PCR-based diagnosis
Various PCR tests are being studied for diagnosing brucel-
losis both at the genus and species levels. These tests have
shown promising results regarding their sensitivity, speci-
ficity and clinical applicability. They have advantages over
the gold standard of culture isolation in that they are easy
to perform, require a short period of time and avoid the risk
of laboratory acquired infection. Once validated, these
diagnostic tests will be the future diagnostic modality of
choice [20,21].
6. Laboratory investigation
All patients suspected of having brucella should have the
following tests done:
1. Complete blood count and differentiation:
The result will be normal in most cases; however, in
some patients variable affection of different cell lines
may be noted such as leukopenia, anemia, thrombocy-
topenia or a combination of some or all of them.
2. Erythrocyte sedimentation rate:
As an acute reactant marker, it will be raised but
usually of modest value ranging from 20 to 80 mm/h.
3. Liver function test:
A mild to moderate elevation of transaminases can be
found in some cases. Increased bilirubin is rare but it can
occur.
4. Renal function test:
Mostly normal; however, in rare cases, glomerulone-
phritis may occur with variable elevations of creatinine
and BUN.
5. Blood culture
Table 1 Drugs used for brucellosis and their dosages.
Drug Dosage
Rifampicin 20 mg/kg/day in two divided doses (max.
600 mg)
Doxycycline 5 mg/kg/day in two divided doses (max.
200 mg) (only for children more than 8
year of age)
TMP/SMX 10 mg of trimethoprim/kg/day (max.
480 mg)
Gentamicin 5e7.5 mg/kg/day IM or IV either as a
single dose or three divided doses
Streptomycin 15 mg/kg IM or IV once daily (max. 1 g/
day) (only for children more than 8 year
of age)
Ciprofloxacin 30 mg/kg/day in two divided doses (max.
1.5 g)
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as indicated.
7. Brucella serology7. Management[4,9,10,11,21,22,23]
Management of brucellosis relies on adherence to the
following criteria:
1. Using an antibiotic that has the ability to act intracel-
lularly and in acidic media.
2. Using combined therapy.Table 2 Regimes for different manifestations of brucellosis.
Disease Therapy
Children < 8 years Ch
Common diseases: Acute
brucellosis, brucella
arthritis, brucella
osteomyelitis, brucella
bacteremia
Rifampicin and septra
OR rifampicin for 45 days
and gentamicin for 7 days
Do
Do
st
Do
ge
Serious illness
Brucella endocarditis
Rifampicin, septra, and
ciprofloxacin
Do
rif
Neurobrucellosis Rifampicin, septra, and
ciprofloxacin
Do
rif3. Using antimicrobials for a prolonged duration according
to the system involved.
There is a limited number of antibiotics that can be used
for the treatment of brucella infections including doxycy-
cline, rifampicin, trimethoprimeesulfamethoxazole,
streptomycin, gentamicin and ciprofloxacin (see Table 1).
- A common combination for children yielding successful
results is as follows:
 Rifampicin and TMP/SMX for children below 8 years of
age.
 Doxycycline and TMP/SMX or rifampicin for children
older than 8 years of age. This combination has been
shown to have the highest success rate and should be
used in children above 8 years to avoid the staining of
the teeth in younger children.
 In serious infections, such as neurobrucellosis and
endocarditis, three to five drugs need to be used for a
longer period of time, usually for three to 12 months
(see Table 2).
 Gentamicin for 7 days or streptomycin for 14 days can
be used for patients requiring hospitalization.
 The use of streptomycin has been associated with a
lesser degree of relapse but is not significantly
superior.
8. Monitoring the response to therapy
8.1. Clinical response
Most patients respond promptly to therapy. Additionally,
most patients with acute brucellosis without neuro-
brucellosis or brucella endocarditis can be managed asComment and duration
of therapyildren > 8 year
xycycline and rifampicin OR
xycycline for 45 days and
reptomycin for 14 days OR
xycycline for 45 days and
ntamicin for 7 days
Hospitalized patients add
gentamicin for 5e7days
Duration of therapy 6 weeks
xycycline, septra, and
ampicin
Gentamicin for the initial two
weeks
Surgical intervention is
indicated
Duration of therapy is 3e9
months
xycycline, septra, and
ampicin
Gentamicin for the initial two
weeks
Ceftriaxone has shown some
efficacy and it is usually used
in the initial therapy for 2e4
weeks
Duration of therapy is 3e6
months up to one year in
complicated cases
Brucellosis in children 45outpatients even if they are bacteremic. They usually
show improvement within 3e7 days after starting therapy.
All patients who are started on therapy for brucellosis
should be followed closely in the clinic to monitor the
persistence of the response and compliance to therapy. In
patients who have CBC laboratory abnormalities, such as a
positive blood culture and/or liver enzymes, they should
have their tests repeated one week after starting therapy.
Such patients usually normalize their laboratory abnor-
malities by then. If culture yields a positive result,
attention needs to be paid to the susceptibility pattern
although most brucella isolates remain sensitive to the
first line antibiotics.
8.2. Serology response
Brucella titers decline slowly and may remain moderately
high for months. Therefore, there is no need to repeat a
titer early in the course of therapy. One serology titer
should be repeated by the end of therapy to evaluate the
trend and demonstrate a decrease in the titer. However,
even if the titer remains high or decrease only slightly this
does not mean that the patient did not respond as some
patients may maintain high titers for a prolonged period of
time. Almuneef et al. demonstrated that a titer over 320
can be sustained for up to 18 months in 25% of patients
after resolution of the infection [16,17].
8.3. Relapse
Among treated patients, 3e9% will have a relapse or rein-
fection. Most relapses occur in the first year following
therapy. If an affected patient begins to have symptoms,
serology and blood culture should be repeated. Sites that
may be affected such as the CNS or heart should be
examined fully. The titer usually will be raised. However,
obtaining an estimation of the IgG and IgM levels separately
is optimal. This can be obtained by the ELISA or SAT with 2-
ME. If the IgG level is high, relapse is indicated. Once
relapse or reinfection occurs, referral to a pediatric in-
fectious disease clinic is warranted for diagnosis confirma-
tion and further management.
8.4. Prevention
1. Increase public awareness about the endemicity of
brucellosis in Saudi Arabia and the importance of
avoiding all risk factors that could lead to acquiring this
infection. This entails stressing the importance of
avoiding drinking raw milk or its products, and avoiding
contact with sick animals or their products such as
aborted fetuses.
2. Animal owners should be aware that brucellosis is
prevalent among animals and thus regular checkups of
animals are required.
3. Avoid mixing different herds of animals together as this
practice facilitates the transmission of disease among
animals.
4. The government should stress the screening of animals,
the vaccination of seronegative animals and slaughtering
diseased ones.5. A collaborative team to implement a brucella control
program should be arranged and maintained among the
concerned government sectors including the Ministry of
Health, the Ministry of Agriculture, the Custom Depart-
ment and the Municipal Department.
6. Screening the family members of patients with acute
brucellosis in endemic areas is strongly recommended to
enhance the detection rate, to initiate early treatment
and to reduce complications.
Where resources are limited, the screening of family
members could be limited to the symptomatic and to
children [24]. In these cases, the cutoff limit for a positive
titer is 1:320.Conflict of interest
There is no conflict of interest.References
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